Navigation Links
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Date:3/20/2017

MENLO PARK, Calif., March 20, 2017 /PRNewswire/ -- Forty Seven Inc., a clinical-stage immuno-oncology company announced today that Mark A. McCamish, M.D., Ph.D., will join the company on May 1 as President and CEO. 

Dr. McCamish, who was most recently Global Head of Biopharmaceutical Development at Sandoz Inc., succeeds the founding CEO, Jonathan MacQuitty, Ph.D. Dr. MacQuitty, who is now a Venture Partner at Lightspeed Venture Partners, will remain on the company's Board of Directors.

"Forty Seven has made unprecedented progress to date based on the remarkable science initiated by the world-class efforts of Dr. Irv Weissman and Dr. Ravi Majeti and their combined team at Stanford University. In addition, Jonathan MacQuitty has assembled an amazing team at the company," said Dr. McCamish. "Forty Seven's technology provides a unique opportunity to harness the power of the innate immune system to help patients defeat their own cancer."

Jonathan MacQuitty said, "Mark has demonstrated exceptional leadership capabilities, as well as a unique combination of late-phase biological drug development, scientific understanding, and a passion for patient benefit that will lead Forty Seven into the future."

Mark has been an executive at several companies including Abbott Labs, Amgen, and PDL Biopharma. Most recently he helped pioneer global biosimilar development at Novartis' Sandoz division. Mark led the Sandoz team at the first ever US FDA Oncology Drug Advisory Committee evaluation of a biosimilar (filgrastim) resulting in a unanimous endorsement and followed that by obtaining a unanimous endorsement of Sandoz' second US biosimilar (etanercept) by the US FDA Arthritis Advisory Committee.  Under his guidance, Sandoz Biopharmaceuticals Development has emerged as a leader in the field having filed several BLA's through September 2016, when Mark retired from Sandoz.

About Forty Seven Inc.

Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in four Phase 1 clinical studies in the US and the UK in patients with solid tumors or cutaneous T-cell lymphoma (CTCL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC).

Forty Seven is located at 1490 O'Brien Drive, Suite A, Menlo Park, CA 94025, U.S.A.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forty-seven-inc-announces-mark-mccamish-md-phd-to-join-as-ceo-on-may-1st-300426601.html


'/>"/>
SOURCE Forty Seven Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Forty of Nations Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
2. Kalorama Information Names Top Seven Companies in Point-of-Care Diagnostics
3. Breckenridge Pharmaceutical signs Marketing Agreement with Gland Pharma Limited for Seven Injectable Products
4. Transformative Potential of Elektas High-field MR-guided Linear Accelerator Highlighted in Seven Abstracts at ESTRO 35
5. Sysmex America, Inc. Named to Center for Companies That Care Honor Roll for Seventh Time
6. Seventeen Organizations Now Utilizing Heritage Provider Networks "QHMO" Suite Of Care Coordination Tools
7. Northern Light Wraps Up Successful 2015 with the Addition of Seven Fortune 1000 Clients
8. Wins Finance Holdings Inc. Enters the Tele-medical Equipment Leasing Sector in China, Signing Seven Agreements Valued at RMB 49.5 Million (US$7.7 Million)
9. Avalon Ventures Expands Collaboration with GSK and Launches Seventh New Company at COI Pharmaceuticals
10. Biophor Diagnostics, Inc. Announces Seventh FDA 510(k) Clearance, Completing Panel of Rapid, Homogeneous Screening Tests for Drugs of Abuse in Oral Fluid
11. Seven US Medical Centers to Acquire Elektas New Leksell Gamma Knife Icon Brain Radiosurgery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the ... a video designed to encourage lawmakers to protect Medicaid funding. , The ... Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, a couple who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
Breaking Medicine News(10 mins):